All In Biotech

Drug Trial Radar · NCT07160725

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Jul 31, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Conditions

  • Solid Tumours

Interventions

  • BMS-986517Drug

    Specified dose on specified days

  • PumitamigDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)Time frame: Up to approximately 2 years
  2. Number of Participants with Serious Adverse Events (SAE)Time frame: Up to approximately 2 years
  3. Number of Participants with AEs meeting protocol-defined Dose-limiting Toxicities (DLTs) criteriaTime frame: Up to Day 21
  4. Number of Participants with AEs Leading to DiscontinuationTime frame: Up to approximately 2 years
  5. Number of Participants with AEs Leading to DeathsTime frame: Up to approximately 2 years

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Local Institution - 0033

    Irvine, California · Not yet recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sanford Cancer Center

    Sioux Falls, South Dakota · Recruiting

  • START - Dallas Fort Worth

    Fort Worth, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Local Institution - 0034

    Guangzhou, Guangdong, China · Not yet recruiting

  • Copenhagen University Hospital Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Herlev and Gentofte Hospital

    Copenhagen, Capital Region, Denmark · Recruiting

  • Odense Universitetshospital

    Odense, Region Syddanmark, Denmark · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Local Institution - 0023

    Madrid, Spain · Not yet recruiting

  • Local Institution - 0026

    Málaga, Andalusia, Spain · Not yet recruiting

  • Local Institution - 0022

    Badalona, Barcelona [Barcelona], Spain · Not yet recruiting

  • Local Institution - 0024

    Barcelona, Barcelona [Barcelona], Spain · Not yet recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.